Farydak Approval History
- FDA approved: Yes (First approved February 23rd, 2015)
- Brand name: Farydak
- Generic name: panobinostat
- Dosage form: Capsules
- Company: Novartis Pharmaceuticals Corporation
- Treatment for: Multiple Myeloma
Farydak (panobinostat) is a histone deacetylase inhibitor for the combination treatment of multiple myeloma.
Development History and FDA Approval Process for Farydak
|Feb 23, 2015||FDA Approves Farydak (panobinostat) for Multiple Myeloma|
|Nov 6, 2014||Novartis Announces Outcome of FDA Advisory Committee Meeting for LBH589 (Panobinostat)|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.